The leading players in the industry are also undergoing product creation and finding market approvals as a result of the rise in the global obesity population. In 2022, Novo Nordisk formed an alliance with Evotec AG to discover and produce drug molecules to treat a variety of metabolic disorders, such as obesity, diabetes, and other related illnesses. The increasing need for medicines that have long-term effects is expected to create enormous opportunities for market vendors to develop new products. This factor is expected to eventually aid the market growth.